Cell Walls Across Clinically Important Organisms: Bacteria, Fungi, and Beyond
Compare cell wall composition across bacteria (peptidoglycan), fungi (chitin, glucan), mycobacteria (mycolic acid), and cell-wall-deficient organisms — and how each difference determines which antimicrobial drugs work against which pathogens.
A single biological fact explains an enormous amount of clinical pharmacology: different microorganisms build their cell walls from completely different materials, and every major class of antimicrobial drug exploits this difference.
Why does penicillin kill bacteria but not fungi? Why doesn't penicillin work on Mycoplasma? Why are antifungal drugs structurally so different from antibacterial drugs? Why is amphotericin B toxic to human kidneys while most antibacterials are not? The answer to all of these questions lies in understanding what each organism's cell wall (or membrane) is actually made of.
This article compares cell wall composition across every clinically important group of microorganisms — and directly connects each difference to the antimicrobial drugs that exploit it.
Why cell wall composition matters more than almost any other biological feature
Unlike many biological structures, the cell wall sits directly at the interface between a pathogen and the drugs we use against it. This single structural feature explains:
- Why some drugs are selectively toxic (safe for humans, deadly for the pathogen) — because the target doesn't exist in human cells
- Why some drugs work on bacteria but not fungi, or vice versa — different cell wall chemistry requires different drug chemistry
- Why certain organisms are intrinsically resistant to entire drug classes — if the target component is absent, the drug has nothing to act on
- Why drug toxicity profiles differ so dramatically — drugs targeting structures that are similar to human cell components tend to be more toxic to patients
Master Comparison Table — Cell Walls of Clinically Important Organisms
| Organism group | Has cell wall? | Main structural component | Unique feature | Drug class that exploits it |
|---|---|---|---|---|
| Gram-positive bacteria | Yes | Peptidoglycan (thick) | Teichoic acids | Beta-lactams, glycopeptides (vancomycin) |
| Gram-negative bacteria | Yes | Peptidoglycan (thin) + LPS outer membrane | Lipopolysaccharide (endotoxin) | Beta-lactams (must cross outer membrane via porins), polymyxins (target LPS) |
| Mycobacteria (acid-fast) | Yes | Peptidoglycan + arabinogalactan + mycolic acids | Waxy, hydrophobic, acid-fast | Isoniazid, ethambutol (target mycolic acid synthesis); rifampicin |
| Mycoplasma | No | None — only a sterol-stabilised plasma membrane | Smallest free-living organism | No cell wall drugs work — must use macrolides, tetracyclines |
| Fungi (yeasts and molds) | Yes | Chitin + β-glucan + mannan (chitin absent in human/animal cells) | Embedded ergosterol-rich plasma membrane beneath the wall | Echinocandins (target glucan), azoles/polyenes (target ergosterol in membrane) |
| Parasitic protozoa (most) | No rigid wall | Pellicle (flexible protein-supported membrane) | No peptidoglycan, no chitin | Different drug classes entirely (antimalarials, antiprotozoals) |
| Protozoan cysts/oocysts (e.g. Cryptosporidium) | Yes — cyst wall | Glycoprotein-based oocyst wall | Extremely resistant to chlorine disinfection | No antimicrobial reliably penetrates; filtration/UV required for water treatment |
| Helminths (worms) | No wall | Tegument (specialised syncytial outer layer) | Different biology entirely | Anthelmintics (target neuromuscular function, not cell wall) |
| Human/animal cells | No | None | Cholesterol-containing plasma membrane only | This is WHY beta-lactams and most antifungals are selectively toxic |
Bacterial Cell Walls
Gram-positive and gram-negative bacteria
Both groups use peptidoglycan (alternating NAG-NAM sugar chains cross-linked by peptide bridges) as their structural scaffold, but differ enormously in thickness and accessory components:
- Gram-positive: thick peptidoglycan (up to 90% of dry wall weight) decorated with teichoic and lipoteichoic acids
- Gram-negative: thin peptidoglycan (~10% of dry wall weight) covered by an outer membrane containing lipopolysaccharide (LPS)
These differences are why beta-lactam antibiotics generally penetrate gram-positive bacteria more easily (no outer membrane barrier) and why gram-negative infections carry the additional risk of endotoxic shock when the bacteria are killed.
Mycobacterial (acid-fast) cell wall
Mycobacteria possess one of the most chemically distinctive cell walls in microbiology — peptidoglycan covalently linked to arabinogalactan, which is in turn linked to extremely long-chain (60–90 carbon) mycolic acids. This waxy, hydrophobic layer:
- Makes the organism resistant to Gram staining (requires acid-fast staining with hot carbol fuchsin instead)
- Provides resistance to most disinfectants and many antibiotics
- Slows growth dramatically (generation time of M. tuberculosis is 15–20 hours vs 20 minutes for E. coli)
- Is the direct target of first-line anti-TB drugs
Drug connection: Isoniazid and ethambutol specifically inhibit mycolic acid synthesis pathways — these drugs have no equivalent target in any other bacterial group, which is why TB requires its own specialised drug regimen rather than standard antibiotics.
→ Mycobacterium tuberculosis: Laboratory Diagnosis
Cell wall deficient bacteria
Mycoplasma and Ureaplasma are the clinically important exception — they have no cell wall at all, only a plasma membrane stabilised with cholesterol scavenged from the host. This single fact makes them completely and permanently resistant to every drug class that targets cell wall synthesis.
→ Cell Wall Deficient Bacteria
Fungal Cell Walls — A Completely Different Chemistry
Fungal cell walls share almost nothing chemically with bacterial cell walls — they are built from completely different polymers, which is exactly why antifungal drugs are structurally and mechanistically unrelated to antibacterial drugs.
Composition of the fungal cell wall
| Component | What it is | Clinical/drug significance |
|---|---|---|
| Chitin | Polymer of N-acetylglucosamine (structurally related to peptidoglycan's NAG but in a different polymer arrangement) | Found in fungal cell walls and arthropod exoskeletons — never in human cells |
| β-1,3-glucan and β-1,6-glucan | Glucose polymers forming the main structural meshwork | Target of echinocandins (caspofungin, micafungin, anidulafungin) |
| Mannan and mannoproteins | Mannose-containing polysaccharides and glycoproteins forming the outer wall layer | Involved in immune recognition (PAMP recognised by host lectin receptors); antigenic — basis of some fungal antigen detection tests |
| Melanin (in some fungi) | Black pigment incorporated into the wall | Cryptococcus neoformans — contributes to virulence and UV/oxidative stress resistance |
Why fungal cell wall biology matters clinically
Fungi are eukaryotic — like human cells, they have a true nucleus, mitochondria, and other organelles. This eukaryotic similarity to human cells is precisely why developing antifungal drugs is so much harder than developing antibacterial drugs: there are fewer uniquely fungal targets to exploit safely.
The cell wall (and the underlying ergosterol-containing membrane) provides the two most important fungal-specific drug targets:
Echinocandins target β-glucan synthase — the enzyme that builds the glucan meshwork. Since human cells have no cell wall at all, this is a highly selective target. Echinocandins are generally very well tolerated.
Azoles (fluconazole, itraconazole, voriconazole) target ergosterol synthesis — ergosterol is the fungal equivalent of cholesterol in the plasma membrane (located just beneath the cell wall). Human cells use cholesterol, not ergosterol, giving azoles reasonable selectivity, though some toxicity occurs because the enzymes involved share similarity with human cholesterol-synthesis enzymes.
Polyenes (amphotericin B, nystatin) bind ergosterol directly, forming pores in the fungal membrane. Amphotericin B's notorious toxicity ("amphoterrible") occurs because it has some affinity for cholesterol too — explaining its nephrotoxicity and infusion reactions in humans.
Read more: Mechanism of Action of Antifungal Drugs
Why Parasites and Helminths Don't Fit This Framework
Unlike bacteria and fungi, most parasitic protozoa (Plasmodium, Giardia, Entamoeba, Trichomonas) do not have a rigid cell wall at all — they are bound only by a flexible plasma membrane, sometimes supported by an underlying protein scaffold called a pellicle. This is why antiparasitic drugs work through entirely different mechanisms (interfering with heme detoxification in malaria, disrupting microtubules, inhibiting folate metabolism) rather than targeting any cell wall structure.
The important exception — protozoan cysts and oocysts: Resting/transmission stages of some protozoa do form a resistant wall:
- Giardia cysts and Entamoeba histolytica cysts have a chitin-containing wall that protects them during environmental transmission
- Cryptosporidium oocysts have a glycoprotein-based wall that is famously resistant to standard chlorine water treatment — this is why Cryptosporidium outbreaks occur even in chlorinated water supplies, and why water treatment relies on filtration and UV disinfection rather than chlorine alone for this organism
Helminths (worms) have an entirely different outer structure called a tegument — a living, metabolically active syncytial layer, not a rigid wall — and are targeted by anthelmintic drugs that disrupt neuromuscular function or glucose uptake rather than any wall component.
Quick Clinical Reference — Matching Drugs to Cell Wall Targets
| If the cell wall/membrane component is... | These drugs work | These drugs don't work |
|---|---|---|
| Peptidoglycan (bacteria) | Beta-lactams, glycopeptides | Antifungals, anthelmintics |
| Mycolic acid (mycobacteria) | Isoniazid, ethambutol | Standard beta-lactams (poor penetration) |
| Absent (Mycoplasma) | Macrolides, tetracyclines, fluoroquinolones | All cell wall-targeting drugs |
| β-glucan (fungi) | Echinocandins | Antibacterials |
| Ergosterol (fungal membrane) | Azoles, polyenes | Antibacterials |
| No wall (most protozoa) | Antiparasitic drugs (different mechanisms) | Antibacterials, antifungals |
| Glycoprotein cyst wall (Cryptosporidium) | Limited drug options; nitazoxanide partially effective | Chlorine disinfection (resistant) |
References and Further Reading
- Madigan, M. T., Bender, K. S., Buckley, D. H., Sattley, W. M., & Stahl, D. A. (2018). Brock Biology of Microorganisms (15th ed.). Pearson.
- Murray, P. R., Rosenthal, K. S., & Pfaller, M. A. (2020). Medical Microbiology (9th ed.). Elsevier.
- Gow, N. A. R., Latge, J. P., & Munro, C. A. (2017). The fungal cell wall: structure, biosynthesis, and function. Microbiology Spectrum, 5(3). https://doi.org/10.1128/microbiolspec.FUNK-0035-2016
- Brennan, P. J. (2003). Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis, 83(1-3), 91–97. https://doi.org/10.1016/S1472-9792(02)00089-6